Czechia· CZ-0222073
AFSTYLA
A coagulation factor viii product containing lonoctocog alfa, registered in Czechia by CSL Behring GmbH, Marburg. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- LONOCTOCOG ALFA
- Manufacturer
- CSL Behring GmbH, Marburg
- Country
- Czechia (CZ)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02220731+1X5ML+AD+STŘ+SETCZK 41542.44
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenAFSTYLA 1000 IE Pulver och vätska till injektionsvätska, lösningCSL Behring GmbH
- NorwayAfstylaCSL Behring GmbH (2)
- PolandAfstylaCSL Behring GmbH
- BelgiumAfstyla 1000 IUCSL Behring
- SpainAFSTYLA 1.000 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLECsl Behring Gmbh
- FinlandAfstylaCSL Behring GmbH
- FranceAFSTYLA 1000 UI, poudre et solvant pour solution injectableCSL BEHRING (ALLEMAGNE)
- IrelandAFSTYLA 1000 IU powder and solvent for solution for injectionCSL Behring GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Afstyla
- Liechtenstein · Afstyla
- Norway · Afstyla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb83d2e1-787d-4bf6-8794-79caddc42646 GET /v1/drugs/eb83d2e1-787d-4bf6-8794-79caddc42646?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ PSO LQF",
"source": "sukl",
"strength": "1500IU",
"pack_size": "1+1X5ML+AD+STŘ+SET",
"substance": "LONOCTOCOG ALFA",
"cz_kod_sukl": "0222073",
"product_type": "BT",
"substance_codes": "20539",
"registration_state": "R",
"registration_number": "EU/1/16/1158/004"
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.